开放合作的资产

ADC资产

抗体药物偶联物（ADCs）结合了抗体的高特异性和小分子药物的强效细胞毒性，实现对癌细胞的精准靶向递送，同时减少对正常组织的损伤。该靶向策略不仅提升了治疗效果，还降低了全身毒性，使ADCs成为治疗难以靶向癌症的有前景的选择。

获取数据包预定会议

双特异性抗体药物偶联物（bsADC）通过同时靶向两种肿瘤相关抗原，旨在降低非肿瘤组织毒性并提升抗肿瘤效果。为助力新型bsADC的研发，我们团队构建了规模化bsADC发现平台，具备以下核心优势：

全人共轻链抗体：我们的RenLite小鼠能够产生遗传多样性的全人源共轻链抗体骨架，这些骨架可组装成Y型双特异性抗体，便于CMC工艺的开发。
新型连接子/毒素系统：采用专有的连接子/毒素系统BLD1102，该系统由超亲水性且可裂解的连接子和新型高效拓扑异构酶I抑制剂药物BCPT02组成，具有强效且显著的旁观者杀伤作用。此外，该系统在食蟹猴体内展现出良好的安全性。

Product Number	Target(s)	Immunization	Discovery Hits selection Leads selection Candidate selection	Preclinical	IND	Phase I	Status
BCG017	PTK7 x EGFR						Preclinical
BCG044	HER3 x EPCAM						Preclinical
BCG040	B7-H4 x B7-H4						Preclinical
BCG041	B7-H3 x MUC1						Preclinical
BCG033	PTK7 x TROP2						Preclinical
BCG023	FOLR1 x MUC1						Preclinical
BCG025	DLL3 x B7-H3						Preclinical
BCG030	DLL3 x SEZ6						Preclinical
BCG016	TPBG x MUC1						Candidate Selection
BCG039	TROP2 x NECTIN-4						Candidate Selection
-	CDH17 x MET						Candidate Selection
-	B7-H4 x EPCAM						Candidate Selection
-	B7-H4 x HER3						Candidate Selection
-	MUC1 x B7-H4						Candidate Selection
-	TROP2 x B7-H4						Candidate Selection
-	FOLR1 x FOLR1						Candidate Selection
BCG026	FAP x GPC1						Candidate Selection
BCG045	MUC1 x TROP2						Candidate Selection
-	MSLN x CDH3						Candidate Selection
-	MET x CDH3						Leads Selection
-	MET x EPCAM						Leads Selection
-	MET x B7-H3						Leads Selection
-	FAP x B7-H3						Leads Selection
-	CDH6 x FOLR1						Leads Selection
-	MUC16 x FOLR1						Leads Selection
-	EGFR x ITGB6						Leads Selection
-	CD142 x NECTIN-4						Leads Selection
-	MUC16 x FOLR1						Leads Selection
-	CDCP1 x B7-H3						Leads Selection
-	CDH3 x EGFR						Leads Selection
-	CLEC12A x CD33						Leads Selection

Product Number	Target(s)	Immunization	Discovery Hits selection Leads selection Candidate selection	Preclinical	IND	Phase I	Status
BCG014	CDH3						CMC
BCG018	ITGB6						CMC
BCG029	ADAM9						Candidate Selection
BCG015	TM4SF5						Candidate Selection
BCG037	PALP						Candidate Selection
BCG047	FOLR1(nano)						Candidate Selection
-	DLL3(nano)						Candidate Selection
-	CLDN1						Candidate Selection
-	MSLN						Candidate Selection
-	HHLA2						Leads Selection
BCG046	CDCP1						Leads Selection
-	EPHA5						Leads Selection
-	CLDN4						Leads Selection
-	CLDN3						Hits Selection

全人TAA抗体库

TAA-targeting antibody backbones available for flexible plug & play
ADAM15	ADAM28	ADAM9	AFP	ALB	AMHR2	AMIGO2
APLNR	AXL	B7-H4	BCMA	CAIX	CCL2	CCR9
CD10	CD105	CD133	CD142	CD155	CD1D	CD200R
CD22	CD226	CD228	CD27	CD28	CD30	CD30L
CD56	CD7	CD70	CD71	CD73	CD74	CD86
CD98	CDCP1	CDH1	CDH11	CDH17	CDH3	CDH6
CEACAM1	CEACAM5	CEACAM6	CHI3L1	CLDN3	CLDN4	CLDN6
CLEC12A	CRTAM	DDR1	DLK1	DLL3	DLL4	DR5
EFEMP1	EGFR	EPHA2	EPHA4	EPHB2	FCRL5	FN1
FOLR1	GPA33	GPA34	GPC-1	GPC3	GPNMB	GPRC5D
GUCY2C	HER2	HER3	HHLA2	HLA-G	HPN	IGFBP2
IL1RAP	IL3RA	ITGA7	ITGB6	JAM-A	KIT	LIV-1
LUNX	LY6G6D	MET	MRC2	MSLN	MUC1	MUC13
MUC16	MUC18	Nectin-4	PDGFRa	PD-L2	PRLR	PSMA
PTK7	ROR1	SEMA4B	SEZ6	SSTR2	TIM1	TPBG
TREM2	TROP2	TWEAKR	TYRO3	and more

百奥赛图与全球多家ADC企业达成了合作关系，包括IDEAYA、ABL Bio、Ona Therapeutics和ADC Therapeutics。联系我们，探索评估、许可或共同开发的机会！

TRODELVY的临床疗效受到其单靶点药物毒性的限制。为扩大治疗窗口并提升疗效，我们致力于开发一种用于治疗转移性三阴性乳腺癌（mTNBC）的TROP2相关双抗ADC
PTK7在乳腺癌中高表达，尤其在三阴性乳腺癌（TNBC）中尤为显著。同时，PTK7在肿瘤起始细胞中也呈富集状态
BCG033是一种新型抗PTK7 × TROP2双抗sADC，在体内实验中展现出优于基准ADC的抗肿瘤疗效